Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹863.90
21.70 (2.58%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹15.47K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
11.0
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹789+9.5%
52W High₹1,226.8-29.6%
Current Price
₹863.90
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹691.12
Upper Circuit₹1,036.68
Reference Price
₹863.90
Investment Checklist
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹768.2
Double Top on 1D (BREAKOUT CONFIRMED) — target ₹777.7
Volume divergence: Bullish (price down, volume up)
RSI at 26.1 — oversold bounce candidate
Composite score -42.71 (SELL) with 50.2% confidence
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
50%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend
EMA20
977.81
EMA50
1028.36
EMA200
967.73
Price Action
DOWNTREND
BEARISH
Higher Highs0
Higher Lows2
Lower Highs9
Lower Lows7
Support & Resistance Levels
Resistance (Above)
₹864.31
₹883.23
₹896.95
₹928.20
₹954.30
Support (Below)
₹849.22
₹839.45
₹804.05
₹790.52
Volume Analysis
TrendINCREASING
Change+54.50%
Unusual VolumeNo
Divergence Detected
Bullish (price down, volume up)
Recent MA Crossovers
20/50 Bearish Cross
4 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹855.26
3% Risk₹837.98
5% Risk₹820.70
7% Risk (Custom)
₹803.43Technical Levels
1x ATR (Volatility)₹821.17
2x ATR (Swing)₹778.44
3x ATR (Trend)₹735.71
Immediate Support₹849.22
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,203.1 Cr | ₹1,328.9 Cr | ₹1,363 Cr | ₹647.3 Cr |
| Net Profit | ₹406.6 Cr | ₹480.7 Cr | ₹518.4 Cr | ₹151.5 Cr |
| EPS | — | ₹26.84 | ₹28.94 | ₹8.46 |
| Operating Profit | ₹607.5 Cr | ₹632.7 Cr | ₹679.2 Cr | ₹216.8 Cr |
ROE
24.79%
ROCE
29.27%
Debt/Equity
0.04
Current Ratio
5.59
OPM
33.49%
NPM
23.40%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 18 Feb 2026 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
| 20 Nov 2025 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
| 19 Aug 2025 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 18 Feb 2025 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
| 27 Nov 2024 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for NATCOPHARM
View AllNEWS
positive
Business Standard - Markets 10d ago
Lupin and alliance partner Natco receive USFDA approval for Eribulin Mesylate Injection
Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
LUPINNATCOPHARMHealthcare
positive
NDTV Profit 11d ago
Stock Picks Today: Dixon Tech, Natco Pharma, Ather Energy, NMDC And More On Brokerages' Radar
Brokerages' Radar
ATHERENERGDIXONENERGYGKENERGYKPELNATCOPHARMNMDCTECHZTECHAutomobile and Auto ComponentsConstruction
positive
NDTV Profit 12d ago
Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit
Buy Sell Hold
BANKINDIAHDFCBANKHDFCNIFBANHDFCPSUBKHDFCPVTBANINFRAJSWHLJSWINFRANATCOPHARMSUZLONWOCKPHARMAZAGGLECapital GoodsFinancial Services